1 The EIC Accelerator Project

EIC Accelerator Program Overview

The European Innovation Council (EIC) Accelerator program is a funding initiative designed to support innovative startups and small to medium-sized enterprises (SMEs) in Europe. The program aims to foster the development of groundbreaking technologies and solutions, particularly in the deep tech sector, which encompasses advanced technologies that often require significant research and development. The EIC Accelerator provides a unique combination of financial support through grants and equity investments, enabling companies to scale their operations and enhance their market presence.

Funding Structure

Under the EIC Accelerator, funding is available in two primary forms: grants and equity investments.

Purpose in the Deep Tech Ecosystem

The EIC Accelerator plays a pivotal role in the European deep tech and startup ecosystem. By providing financial support, the program aims to reduce the risks associated with innovation and encourage entrepreneurs to pursue ambitious projects that address pressing societal challenges. The EIC Accelerator specifically targets sectors that are often underfunded, such as biotechnology, advanced materials, and artificial intelligence. By supporting these sectors, the program seeks to drive economic growth, create jobs, and foster technological advancements within Europe.

Role in Scaling Companies

One of the key objectives of the EIC Accelerator is to assist companies in scaling their operations. By offering substantial financial backing, the program enables startups to move beyond the initial development phase and into market readiness. The funding can be used for a variety of purposes, including product development, market entry, and scaling production capabilities. Moreover, the EIC Accelerator provides access to a network of investors and mentors, helping companies to secure additional funding and strategic partnerships from the private sector. This dual approach not only strengthens the company’s financial foundation but also enhances its market competitiveness.

EIC Accelerator Winner: Nemesis Bioscience Limited

Nemesis Bioscience Limited, a UK-based startup, is a notable winner of the EIC Accelerator. The company’s project, known by the acronym Transmids, focuses on the urgent issue of antimicrobial resistance (AMR).

Project Overview: Transmids

The Transmids project aims to inactivate AMR genes present in the gut microbiome of animals and prevent the horizontal transmission of these genes. This project is crucial, as AMR poses a significant threat to both human and animal health, leading to treatment failures and increased healthcare costs.

Technology Basics and Background

The technology underpinning Transmids is based on advanced biotechnological approaches to modify the gut microbiome. The gut microbiome is a complex community of microorganisms that play a critical role in digestion, immunity, and overall health. However, the presence of AMR genes within this microbiome can lead to the spread of resistant bacteria, complicating treatment options for infections.

Nemesis Bioscience is developing innovative solutions that target and inactivate these AMR genes, thereby reducing the risk of resistance spreading among bacterial populations. The project focuses on creating specific agents capable of disrupting the genetic mechanisms that confer resistance, thus restoring the effectiveness of conventional antibiotics.

The implications of this technology are far-reaching. By targeting AMR at its source within animal populations, Transmids has the potential to significantly reduce the prevalence of resistant bacteria, ultimately benefiting both animal and human health. Additionally, this innovative approach can contribute to safer food production practices, enhancing public health outcomes.

In summary, the EIC Accelerator program, through its funding mechanisms and strategic support, plays a vital role in nurturing innovative startups like Nemesis Bioscience. By addressing critical challenges such as antimicrobial resistance, these initiatives not only foster technological advancement but also contribute to the broader goals of public health and economic growth in Europe.

2 The Funding Rounds

Nemesis Bioscience Limited, a biotechnology company based in the United Kingdom, has been a notable player in the fight against antimicrobial resistance. The company's innovative approach involves developing technologies to switch off resistance mechanisms rather than killing bacteria, thereby extending the lifespan of existing antibiotics.

Financing and Funding Rounds

Nemesis Bioscience has completed several funding rounds to support its research and development. In May 2017, the company successfully raised more than £700,000 in a seed funding round led by The Rainbow Seed Fund, with co-investment from Finance Wales and Dr. Mark McCamish. This funding was used to validate its Bacterial Cybergenetics technologies, including Nemesis Symbiotics and Transmids, which aim to combat antibiotic resistance by inactivating resistance genes and ensuring antibiotics remain effective.

Later, in June 2018, Nemesis Bioscience announced another seed funding round of £1.4 million, which included investment from Shionogi & Co. Ltd.. These funding rounds highlight the company's ability to attract strategic investors who recognize the potential of its technology.

Investor Information

Key investors in Nemesis Bioscience include: - The Rainbow Seed Fund: A leading investor in the 2017 funding round.

• Finance Wales: Provided seed funding and follow-on investments.
• Dr. Mark McCamish: Co-investor in the 2017 round.
• Shionogi & Co. Ltd.: Participated in the 2018 funding round.

Funding Timing and Amounts

• May 2017: More than £700,000 raised in a seed funding round.
• June 2018: £1.4 million raised in another seed funding round.

Company Valuation and Exit Events

As of now, there is no publicly available information on Nemesis Bioscience's company valuation or any exit events such as IPOs or acquisitions. The company continues to focus on developing its unique approach to combat antimicrobial resistance.

Additional Information

Nemesis Bioscience's technology has been recognized for its potential to address the global crisis of antibiotic resistance. The company's strategies are designed not only to restore antibiotic efficacy but also to prevent the spread of resistance genes. This approach is critical in maintaining the effectiveness of both current and future antibiotics.

EIC Accelerator Funding

Nemesis Bioscience won the EIC Accelerator funding in 2022, following a successful Step 3 interview. This funding supports the company's further development and scaling of its innovative technologies.

Sources

• Nemesis Bioscience Closes Funding Round And Begins Preclinical Programmes
• Nemesis Bioscience company information, funding & investors
• Nemesis Bioscience closes funding round and begins preclinical programmes
• Nemesis Bioscience funding
• Nemesis Bioscience completes funding round
• NEMESIS BIOSCIENCE LTD Information
• Milner facilitates strategic partnership between Nemesis and Shionogi
• Nemesis Biosciences Ltd.

3 The Press Releases

Nemesis Bioscience's Post-EIC Accelerator Developments London-based Nemesis Bioscience, which secured a €2 million EIC Accelerator grant in July 2022, focuses on combating antimicrobial resistance (AMR) using CRISPR-based technologies. Their approach centers on deactivating bacterial resistance mechanisms rather than killing pathogens, aiming to restore efficacy to existing antibiotics.

Key Updates and Technologies:

• CRISPR-Cas9 Platform: The company’s Nemesis Symbiotics© and Transmid© systems employ modified CRISPR arrays to target beta-lactamase genes (e.g., VIM, OXA, NDM) across multidrug-resistant bacteria like E. coli. These systems also prevent horizontal gene transfer of resistance traits via probiotic delivery.
• Leadership Expansion: In July 2022, Dr. Yoshinori Yamano joined as a non-executive director, bringing expertise from collaborations with Japanese pharmaceutical firms like Shionogi.
• Preclinical Progress: Earlier work (2017–2018) demonstrated in vivo validation of their Cybergenetics© platform targeting beta-lactamases, supported by £1.4M seed funding involving Shionogi and Finance Wales.

No press releases directly from nemesisbio.com are available in the provided sources. However, third-party updates highlight ongoing preclinical programs and international partnerships post-EIC funding.

---

Sources
Nemesis Bioscience awarded €2m EIC accelerator grant
Nemesis Bioscience’s CRISPR approach
Milner facilitates partnership with Shionogi
Nemesis closes funding round for preclinical programs
Dr. Yamano joins board

4 The Technology Advancements

Overview of Nemesis Bioscience Limited

Nemesis Bioscience Limited, a UK-based company, is known for developing innovative technologies to address antibiotic resistance. One of their key technologies involves the use of DNA constructs called Transmids, which do not directly kill bacteria but aim to mitigate antibiotic resistance by modifying bacterial behavior.

Current Capabilities

Nemesis Bioscience has been working on pioneering technologies to revive anti-microbial therapies rendered ineffective by microbial resistance. Their approach focuses on preventing antibiotic-resistant infections and treating them effectively. The company utilizes CRISPR-Cas9 systems as part of their strategy to combat resistance.

Advancements Since EIC Accelerator Funding

As of the latest available information, Nemesis Bioscience was selected for the EIC Accelerator funding in 2022. However, specific advancements or updates related directly to this funding in March 2022 are not detailed in the public domain. The EIC Accelerator supports innovative companies that address significant societal challenges, and Nemesis Bioscience's selection indicates its promising approach to tackling antimicrobial resistance.

Technology Improvements and Market Demonstrations

While there is no detailed information on new features or improvements specifically linked to the EIC Accelerator funding, Nemesis Bioscience's unique approach using DNA therapies like Transmids suggests ongoing development in this area. The company's technologies are designed to address critical clinical problems by preventing resistance, but there is no recent data on market demonstrations, customer trials, or clinical trials directly tied to this funding.

Patents and Scientific Publications

There are no recent updates or mentions of Nemesis Bioscience filing new patents, publishing scientific studies, or conducting clinical trials specifically after receiving the EIC Accelerator funding. However, the company continues to be recognized for its use of CRISPR technology in developing antibacterial solutions.

Conclusion

Nemesis Bioscience remains a significant player in the effort to combat antibiotic resistance, leveraging technologies like CRISPR to develop innovative solutions. While specific advancements or milestones post-EIC Accelerator funding are not extensively documented in the public domain, their continued focus on addressing antimicrobial resistance underscores their potential impact in this critical area.

Sources:

• Milner facilitates strategic partnership between Nemesis and Shionogi
• Nemesis Bioscience | Cambridge Network
• Global Microbial Gene Editing Services Industry is anticipated to achieve a remarkable US$ 3.05 billion
• Executive Summary - Infex Therapeutics
• List of bankrupt, sold, merged, or otherwise defunct biotech, pharma companies
• Most competitive EIC Accelerator cut-off awards major funding round
• Nemesis Bioscience company information, funding & investors
• EIC Accelerator 23 March cut-off

5 The Partnerships and Customers

Nemesis Bioscience Limited: Partnerships and Developments

Nemesis Bioscience Limited, based in the United Kingdom, is a biopharmaceutical company focused on developing innovative solutions to combat antibiotic resistance. In March 2022, the company received funding from the EIC Accelerator, marking a significant milestone in its growth and development. This section details the partnerships, new relationships, and technological advancements of Nemesis Bioscience since receiving this funding.

Partnerships and Customers

Shionogi & Co Ltd. is one of Nemesis Bioscience's notable partners. In 2018, Shionogi participated in a Seed funding round for Nemesis Bioscience, alongside other investors. While specific new customer names are not detailed in recent reports, Nemesis Bioscience's focus on DNA therapeutics and its pioneering work in using CRISPR-Cas9 systems to address antibiotic resistance suggest potential collaborations with major pharmaceutical companies and research institutions.

Nature of New Relationships

The company's innovative approach, particularly with its Nemesis Symbiotics© technology, offers a unique solution to inactivate antibiotic resistance in bacterial pathogens. This technology not only enhances the effectiveness of existing antibiotics but also prevents the spread of resistance genes among bacteria. Such advancements position Nemesis Bioscience as a leader in the anti-microbial resistance (AMR) landscape, potentially attracting partnerships with entities seeking innovative AMR solutions.

Purpose of Relationships

These relationships are crucial for Nemesis Bioscience as they provide both financial support and strategic partnerships that can aid in scaling up its operations and advancing its technology. Collaborations with pharmaceutical companies can facilitate clinical trials and commercialization of its products, while partnerships with research institutions can enhance its technological capabilities.

Market Positioning

Nemesis Bioscience's receipt of EIC Accelerator funding and its cutting-edge technology position it prominently in the AMR market. The company's focus on DNA therapeutics and its ability to inactivate resistance mechanisms across various antibiotic classes make it an attractive partner for companies seeking solutions to the growing global AMR challenge.

Technology Advancements and Scaling

The relationships and funding Nemesis Bioscience has garnered will significantly contribute to its technology advancements and scaling efforts. By collaborating with major pharmaceutical companies and leveraging the EIC Accelerator funding, Nemesis Bioscience can accelerate the development and commercialization of its products. This will allow the company to expand its reach and impact in the fight against antibiotic resistance, potentially leading to the widespread adoption of its innovative technologies.

Sources

• Milner Facilitates Strategic Partnership Between Nemesis and Shionogi
• Nemesis Bioscience - Bacteriophage.news
• NEMESIS BIOSCIENCE LTD overview

6 The Hiring and Company Growth

Overview of Nemesis Bioscience Limited

Nemesis Bioscience Limited, a UK-based biotechnology company, has been recognized for its innovative approach in tackling antibiotic resistance through its Nemesis Symbiotics technology. This technology aims to restore the efficacy of existing antibiotics by inactivating bacterial resistance mechanisms.

Key Facts and Developments

Founding and Location: Nemesis Bioscience was founded in 2014 and is based on the Babraham Research Campus, Cambridge, UK. However, its registered office is currently listed at 32 London Bridge Street, Londonassistant

Overview of Nemesis Bioscience Limited

Nemesis Bioscience Limited, a UK-based biotechnology company, has been recognized for its innovative approach in tackling antibiotic resistance through its Nemesis Symbiotics technology. This technology aims to restore the efficacy of existing antibiotics by inactivating bacterial resistance mechanisms.

Key Facts and Developments

• Founding and Location: Nemesis Bioscience was founded in 2014 and is based on the Babraham Research Campus, Cambridge, UK. However, its registered office is currently listed at 32 London Bridge Street, London.
• Current Status: The company was dissolved on 2 May 2024.
• Team and Hiring: As of recent data, Nemesis Bioscience had a small team size, with reports indicating only a few employees. There is no current information available on whether they are hiring, as the company has been dissolved.
• Growth and Scaling: Prior to its dissolution, Nemesis Bioscience was involved in significant technological developments but did not achieve substantial team growth due to its small size.
• Recent Appointments: In 2022, Nemesis Bioscience appointed Dr. Yoshinori Yamano as a non-executive director, bringing valuable expertise in antibacterial drug development to the company.
• Impact and Future Prospects: Although Nemesis Bioscience's technology held promise for addressing antibiotic resistance, the company's dissolution means that it will not continue to scale or grow. The appointment of Dr. Yamano was intended to support the commercialization of their technology, but this is no longer possible.
• Management Changes: The company was led by CEO Frank Massam, with Dr. Yamano joining as a non-executive director. However, no other major changes in the founding team have been reported.

Conclusion

Nemesis Bioscience Limited's journey highlights the challenges faced by small biotechnology companies in maintaining operations and achieving growth, despite innovative technologies and recognition.

Sources:

• NEMESIS BIOSCIENCE LTD Information - RocketReach
• Nemesis Bioscience Ltd overview - Companies House - GOV.UK
• Nemesis bioscience announces the appointment of Dr Yoshinori Yamano as non-executive director

7 The Media Features and Publications

Overview of Nemesis Bioscience Limited

Nemesis Bioscience Limited, a UK-based biopharmaceutical company, has been making significant strides in the fight against antibiotic resistance since receiving EIC Accelerator funding in March 2022. Founded in 2014, the company is pioneering innovative technologies designed to revive antimicrobial therapies rendered ineffective by increasing microbial resistance.

Media Features and Publications

Nemesis Bioscience Limited has been featured in various publications, including reports on the antibiotic resistance market. For instance, a market forecast by InsightAce Analytic highlighted the growing need for solutions like those offered by Nemesis Bioscience, projecting the antibiotic resistance market to reach $18.34 billion by 2030. However, specific mentions of Nemesis Bioscience in mainstream media are limited, with most information available through industry-specific databases and news releases.

Content from Publications

Publications focus on the company's unique approach to combating antibiotic resistance. Nemesis Bioscience develops DNA therapies known as Nemesis Symbiotics, which can be administered before antibiotics to inactivate resistance mechanisms in bacterial pathogens. This technology applies to all antibiotic classes and bacteria types, offering potential for both treatment and prevention of AMR infections.

Podcasts and Interviews

There is no publicly available information on specific podcasts or interviews featuring the team from Nemesis Bioscience Limited. However, the company's innovative approach likely attracts interest from bio-science communities, which could lead to future interviews or discussions in scientific forums.

Conference and Fair Visits

Nemesis Bioscience Limited may participate in scientific conferences and events focused on antimicrobial resistance and biotechnology, but specific details on their participation in such events are not readily available. Given the company's focus on pioneering antimicrobial solutions, it is plausible they engage with relevant conferences to showcase their technologies.

Involvement in Events

The company's involvement in events is likely centered around showcasing their innovative technologies and networking within the biopharmaceutical industry. While specific event participations are not documented, Nemesis Bioscience's work aligns with global efforts to combat antimicrobial resistance, suggesting they could be active in relevant scientific and industry forums.

Sources: - Nemesis Biosciences Ltd. - Drug pipelines, Patents, Clinical trials

• Nemesis Bioscience - Bacteriophage.news
• Antibiotic Resistance Therapeutics Market Research Report
• Nemesis Bioscience company information, funding & investors
• Nemesis Bioscience